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Background/aim: Capecitabine is a prodrug of 5-fluorouracil and has shown significant antitumor activity. The main adverse effects
are hand-foot syndrome, diarrhea, and dermatitis. In recent years, hypertriglyceridemia has been reported in patients treated with
capecitabine. Dyslipidemia is a rare but important side effect of capecitabine. The aim of this study is to examine the changes in lipid
levels during capecitabine treatment and to raise awareness of pharmacovigilance.
Materials and methods: In this retrospective study, it was aimed to analyze lipid metabolism after capecitabine treatment and is
intended to contribute to the formation of a pharmacoepidemiological database. For this purpose, triglyceride, cholesterol, HDL, LDL,
ALT, AST, ALP, MCV, and Hb blood levels of 57 patients treated with capecitabine at the Department of Medical Oncology, Faculty of
Medicine, Çukurova University, were examined before and after five cycles of treatment.
Results: Blood triglyceride and cholesterol levels were significantly increased after capecitabine treatment. The increase in triglyceride
levels was higher than the increase in cholesterol levels.
Conclusion: In the light of these findings, monitoring of the lipid profile should be considered in cancer patients treated with capecitabine.
Key words: Capecitabine, triglycerides, cholesterol

1. Introduction
Antineoplastic drugs have many side effects and have impact
on quality of life. Severity and frequency of the side effects
vary depending on each person and the type of drugs. It is
necessary to track and thus prevent possible side effects (1–
4). Capecitabine is a prodrug of 5-fluorouracil (5-FU) used
primarily on colorectal and metastatic breast, ovarian, and
pancreas cancers as a single agent or in combination with
other antineoplastic agents. The standard dose for treatment
is 2500 mg/m2 for 14 days with 21 days of cycle in the form
of 2 doses taken twice a day (1–4). The most common side
effects of capecitabine are hand-foot syndrome, diarrhea,
and dermatitis (3,4). Moreover, hyperbilirubinemia, nausea/
vomiting, constipation, epigastric pain, and dermatitis can
be observed as well. In recent years, hypertriglyceridemia
has been reported in patients treated with capecitabine.
However, the etiology and the rate of capecitabine induced
hypertriglyceridemia are not clear (5–7).
The aim of the present study was to examine the
changes in lipid levels after taking capecitabine and to raise
awareness in terms of pharmacovigilance.
* Correspondence: nurselisci@gmail.com
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2. Materials and methods
The research is based upon the data collected from patients
treated with capecitabine between November 2010 and
February 2015 in the Department of Medical Oncology
and for whom there was sufficient laboratory data. Lipid
profiles of these patients were evaluated with control tests
before and after capecitabine treatment.
Demographical properties of the patients including
age and sex, comorbid conditions (dyslipidemia/diabetes
mellitus (DM), type and stage of cancer, treatment
regimen, the levels of triglyceride, cholesterol, high density
lipoprotein (HDL), low density lipoprotein (LDL), alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), hemoglobin (Hb), and
mean corpuscular volume (MCV) levels were registered.
Data accordance with normal distribution was tested; t
test and paired samples t test were used for the continuous
variables normally distributed and for the continuous
variables that are not normally distributed, Wilcoxon’s test
was used. For the analysis of categorical variants, the chisquare test was used.
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Table 1. Characteristics of patients.
Characteristics

n (%)

Patients

57

Mean age

56.1 ± 11.5

Female/male

46/11

Tumor type
Breast
Colorectal
Other

37 (61.4)
9 (15.8)
13 (22.8)

DM

13

Dyslipidemia

21

Therapy
Capecitabine
Combination
with capecitabine

20 (35)
37 (65)

Triglyceride

3. Results
A total of 57 patients were treated with capecitabine in
cases of breast, colon, gastric, lung, pancreas, rectum,
and renal cell cancer. Thirteen patients had DM, while 21
patients had dyslipidemia before capecitabine treatment
(Table 1).
After 5 cycles of capecitabine treatment, triglyceride
median level of patients increased from 170 (69–657) mg/
dL to 321 (228–871) mg/dL and cholesterol average level
increased from 187.7 ± 50 mg/dL to 242.3 ± 52.7 mg/dL
and these increases were statistically significant (P < 0.01).
While in patients with no history of dyslipidemia the
median triglyceride level was 137 (69–197) mg/dL before
treatment, this level increased to 292 (228–542) mg/dL.
On the other hand, for the patients with dyslipidemia,
triglyceride median level was 223 (135–560) mg/dL before
treatment and this level increased to 466 (251–871) mg/dL
after treatment (Figure 1).
Cholesterol average level of patients without a history
of dyslipidemia was 164.4 ± 36.1 mg/dL before treatment
and this level increased to 238.7 ± 62.1 mg/dL after
treatment. Cholesterol average level of patients with a
history of dyslipidemia was 227.7 ± 45.4 mg/dL before
treatment and this level increased to 248.8 ± 34.8 mg/dL
after treatment (Figure 2).
Triglyceride median levels in patients with no history
of DM were 161.5 (69–657) mg/dL and 292 (228–620) mg/
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Figure 1. Triglyceride levels of patients with and without
dyslipidemia (DL).
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Figure 2. Cholesterol levels of patients with and without
dyslipidemia (DL).

dL before and after capecitabine treatment, respectively.
Triglyceride median levels in patients with a history of DM
were 187.5 (125–436) and 668.5 (331–871) mg/dL before
and after capecitabine treatment, respectively (Figure 3).
Cholesterol average levels in patients without a history
of DM were 183.3 ± 40.3 mg/dL and 235.7 ± 50.5 mg/
dL before and after capecitabine treatment, respectively.
Cholesterol average levels of diabetic patients were 210.1
± 50.2 mg/dL and 257.3 ± 35.8 mg/dL before and after
capecitabine treatment, respectively (Figure 4).
HDL, LDL, AST, ALT, ALP, and Hb levels before and after
treatment did not show significant change (P > 0.05).
MCV levels were higher after treatment compared to
pretreatment levels (P < 0.05) (Table 2).
4. Discussion
Changes in lipid profile in cases treated with capecitabine
were examined in 57 patients. Cholesterol and triglyceride
levels were increased in patients treated with capecitabine
but changes in HDL and LDL levels were not significant
after capecitabine treatment. Moreover, there were no
changes in the levels of ALT, AST, or ALP.

1207

SÜRMELİOĞLU et al. / Turk J Med Sci
350

800

300
250

600
500
DM (-)

400
300

Total

200

DM (+)

100
0

Cholesterol

Triglyceride

700

0

1

2
3
Cycle

4

200

DM (-)

150

Total

100

DM (+)

50
0

5

Figure 3. Triglyceride levels for patients with and without DM.

0

1

2

3
Cycle

4

5

Figure 4. Cholesterol levels for patients with and without DM.

Table 2. MCV levels of the patients for before and after (1–5) the capecitabine treatment.

MCV* fL

Before

1

2

3

4

5

85.7 ± 8.3

88.8 ± 9.6*

91.4 ± 11.5*

90.1 ± 12.6*

86.5 ± 9.8

86.8 ± 9.5

Average ± SD (*P < 0.05)

Although National Cancer Institute Common Toxicity
Criteria grade 3 or 4, hypertriglyceridemia is listed in the
manufacturer’s product literature and has been reported
as an uncommon (0.1%–1%) toxicity (5–15). Data about
the effect of capecitabine on lipid profile for clinical
practice are limited. For example, strong decreases in HDL
levels after capecitabine (from 46 to 4.8 and 114 to 32)
in 2 cases have been reported by Duman et al. (5). In a
prospective study, hypertriglyceridemia has been reported
in 3.7% of 304 cases and this is important information
for clinicians to be aware of the risks of abnormal lipid
profile in patients treated with capecitabine (6). The
incidence of hypertriglyceridemia was found to be higher
than that of hypercholesterolemia by Bar-Sela et al.
and 4 severe and 19 mild cases of hypertriglyceridemia
and hypercholesterolemia were reported in their study
covering 102 cases (7).
It is very well known that hypertriglyceridemia and
hypercholesterolemia may be related to diet, weight
gain, obesity, alcohol consumption, diabetes mellitus,
and nephrosis (5,7–13). However, the declining trend
in lipid levels after capecitabine cessation supports the
correlation between capecitabine and dyslipidemia. In our
study group 13 patients had a history of diabetes mellitus
and 21 patients had dyslipidemia. Increases in levels of
triglyceride and cholesterol were greater in these patients.
This situation suggests that clinicians must be more careful
about lipid profile in patients with diabetes mellitus and/
or dyslipidemia when planning capecitabine treatment
and antilipemic treatment if necessary. Since capecitabine
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is given for longer in many cases, this will be vital for
morbidity in the cases. It is very important in patients with
cancer and comorbid conditions.
Although the etiology of capecitabine-induced
hypertriglyceridemia and hypercholesterolemia is
unknown, there are 3 hypotheses about this association
(5–7,10–16). The first of these mechanisms is related
to thymidine phosphorylase. It is well known that
capecitabine is converted by thymidine phosphorylase
to 5-FU. Because a previous study investigating the
eﬀect of 5-FU on serum lipid levels showed a signiﬁcant
reduction in total cholesterol in both patients and
animals, hypertriglyceridemia may be attributed either
to capecitabine itself or to precursor of 5-FU (5–7,11–
16). The second is related to a lipoprotein lipase (LPL)
defect. A defect of LPL is linked with an accumulation
of chylomicrons and/or of very low-density lipoprotein
(VLDL) (6,7,10,12–16). Kurt et al. suggest that CIHT may
appear more readily in individuals with hereditary LPL
deficiency (14). It is worth noting that LPL defect also occurs
in the case of an increase in its inhibitor (apolipoprotein
CIII) and/or a decrease in its activator (apolipoprotein
CII). However, the link between capecitabine and
apolipoprotein CII/CIII levels has never been explored
(6,7,10,12–16). The third is capecitabine causes pancreatic
inflammation and this inflammation causes hyperglycemia
and hypertriglyceridemia (5,10,12,13). Triglyceride levels
have been found to be increased from 270 to 9063 mg/
dL and glucose levels have been found to be increased
from 90 to 350 mg/dL in 2 cases reported by Duman et
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al (5). Similar increases have been reported by Han and
Huang (13). In the present study, in order to understand
the relations of triglyceride and cholesterol levels with liver
enzymes levels of ALT, AST, and ALP were observed and
no statistically meaningful relations were found.
A significant increase in MCV was found in our
patients after capecitabine treatment. We did not find
folate or vitamin B12 deficiency in our patients. This has
been attributed to capecitabine-induced macrocytosis as
suggested by Jung and Wenzel (17,18).

In conclusion, capecitabine causes disturbances
in the serum lipid profile especially in patients with
underlying dyslipidemia and/or diabetes mellitus. Since
hypertriglyceridemia has serious acute and chronic
metabolic complications (such as acute pancreatitis),
serum lipid levels must be closely monitored in patients
with diabetes and dyslipidemia under capecitabine
treatment. Increase in MCV during capecitabine treatment
is an interesting finding and the pathogenesis is not clear.

References
1.

Kayaalp OS. Akılcıl Tedavi Yönünden Tıbbi Farmakoloji. 13th
ed. Ankara, Turkey: Pelikan; 2012 (in Turkish).

2.

Katzung BG, Masters BS, Trevor AJ. Temel ve Klinik
Farmakoloji. 12th ed. İstanbul, Turkey: Nobel Tıp; 2014 (in
Turkish).

3.

Walko CM, Lindley C. Capecitabine: a review. Clinical
Therapeutics 2005; 27: 42-44.

4.

Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics
of capecitabine. Clin Pharmacokinet 2001; 40: 85-104.

5.

Bozkurt-Duman B, Paydas S, Tetiker T, Gunaldı M, Usul Afsar
C, Erçolak V, Haksöyler V, Şimşek-Dilli M. Capecitabineinduced hypertriglyceridemia and hyperglycemia: two cases.
Pharmacology 2012; 90: 212-215.

6.

Michie CO, Sakala M, Rivans I, Strachan MW, Clive
S. The frequency and severity of capecitabine-induced
hypertriglyceridaemia in routine clinical practice: a prospective
study. Brit J Cancer 2010; 103: 617-662.

7.

Bar-Sela G, Cohensiuis-Kent D, Kornikova O, Haim N.
Increase in triglyceride blood level in patients treated with
capecitabine: a retrospective survey. Anti-Cancer Drug 2014;
25: 729-734.

8.

Seminara P, Losanno T, Emiliani A, Manna G. Cancer
chemotherapy and cardiovascular risks: is capecitabineinduced hypertriglyceridemia a rare adverse effect? Cardiology
2010; 116: 42-44.

9.

Bar-Sela G, Haim N. Uncontrolled hypertriglyceridemia
induced by capecitabine: case report and review of the
literature. Cancer Chemoth Pharm 2009; 63: 779-782.

10.

Garg R, Angus E, Fincher S. Capecitabine-induced severe
hypertriglyceridaemia and diabetes: a case report and review
of the literature. Diabetic Med 2009; 26: 1308-1309.

11.

Orphanos GS, Stavrou NG, Picolos MK. Hypertriglyceridemia:
an underdiagnosed side effect of capecitabine chemotherapy.
Acta Oncol 2010; 49: 262-263.

12.

Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP.
Capecitabine-induced hypertrigyceridemia: a report of two
cases. Anticancer Res 2006; 26: 2249-2252.

13.

Han G, Huang JX. Hypertriglyceridemia and hyperglycemia
induced by capecitabine: a report of two cases and review of
the literature. J Oncol Pharm Practice 2014; 21: 380-383.

14.

Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N.
Capecitabine induced severe hypertriglyceridemia: report of
two cases. Ann Pharmacother 2006; 40: 328-331.

15.

Polinder-Bos HA, Kok EE, Van de Wiel A, Spiering W, Wielders
JP, Bloemendal HJ. Severe hypertriglyceridaemia associated
with the use of capecitabine. Neth J Med 2012; 70: 104.

16.

Javot L, Spaeth D, Scala-Bertola J, Gambier N, Petitpain N,
Gillet P. Severe hypertriglyceridaemia during treatment with
capecitabine. Brit J Cancer 2011; 104: 1238-1239.

17.

Jung HA, Kim HJ, Maeng CH, Park SH, Lee J, Park JO, Park YS,
Lim HY, Kang WK. Changes in the mean corpuscular volume
after capecitabine treatment are associated with clinical
response and survival in patients with advanced gastric cancer.
Cancer Res Treat 2015; 47: 72-77.

18.

Wenzel C, Mader RM, Steger GG, Pluschnig U, Kornek GV,
Scheithauer W, Locker GJ. Capecitabine treatment results
in increased mean corpuscular volume of red blood cells in
patients with advanced solid malignancies. Anticancer Drug
2003; 14: 119-123.

1209

